How will the New Administration Impact the US Pharma Market?

Watch Video

How will the New Administration Impact the US Pharma Market?

This webinar originally aired as part of CPhI Discover - 17-28 May 2021

In January 2021, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) started operating under the new U.S. administration.

The 2020 presidential campaign and global leaders prioritised COVID-19 vaccines, treatment, and new technologies to identify, cure and reduce the transmission of the virus. Therefore, without doubt, these topics will continue to have a profound relevance during the coming years. However, there is also a great interest to see what changes lie ahead in other broader areas, namely reshoring manufacturing, partnering, drug pricing, patient access and M&A.

This session will bring together experts to analyse the global landscape and forecast what this new era means for Pharma.

  • Key issues for the global regulatory agencies to address new diseases and financial challenges worldwide: Transition and differences in policies and priorities
  • Generic and Biosimilar Competition Landscape:
  • Efforts to modernize drug manufacturing
  • Approach to patent and exclusivity issues
  • Promote generic and biosimilar competition to reduce drug prices
  • Regulatory modernization and globalization responses
  • Supply Chain, Re-shoring, Drug Shortages: Plans to address shortages/disruptions and promoting risk readiness for manufacturing capacity
  • COVID-19 highlights the importance of innovation and flexibility in health system preparedness
  • Other Content from CPhI